Experimental and Molecular Medicine Impact Factor

The useful signal here is the combination of a 12.9 JIF and a 14.2 five-year JIF. That tells you the journal's better papers are not just catching a short translational buzz cycle. They keep getting used because they remain relevant at the disease-mechanism level.

The journal's identity matters too. EMM occupies a specific lane: mechanistic biomedical work with a credible disease or therapeutic consequence. It is not a pure basic-science journal, and it is not a clinical outcomes journal either.

That is why the number can feel higher than authors expect for a journal that lives between those worlds. The journal is strong precisely because it does that middle lane well.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 9.18 in 2023 to 12.18 in 2024, and dramatically above the mid-2010s range. That is consistent with a journal that has become more visible as translational and disease-relevant molecular work has become more competitive.

The trend is not perfectly smooth. But the broader line is clear: EMM's citation position is substantially stronger than it was a decade ago.

The common mistake is to read the JIF and assume EMM will take any clean mechanistic paper if the biology is interesting enough.

That is usually not the real bar. EMM works best when the manuscript connects:

• a molecular mechanism
• a disease or pathophysiology problem
• a believable translational consequence
• a package strong enough to survive outside a narrow specialty niche

If the disease relevance is generic, or the translational angle is mostly aspirational, the fit often weakens quickly.

In our pre-submission review work on manuscripts targeting EMM, the recurring problem is not lack of science. It is lack of a clean translational story. Authors often have a mechanism, a disease context, and a hopeful implication, but the manuscript still reads like three parallel claims rather than one integrated argument.

EMM usually rewards papers where disease meaning is explicit from the start.

In our pre-submission review work on manuscripts targeting Experimental and Molecular Medicine, four failure patterns recur.

Omics or bioinformatics signal without enough experimental follow-through. The associations may be strong, but the causal bridge is still too thin.

Disease framing stays generic. The manuscript names a disease context without showing why the finding actually changes disease understanding or therapeutic logic.

Therapeutic language outruns the data. This is common when a mechanism paper starts making treatment claims before validation justifies them.

The story feels broad but not sharp. EMM usually prefers a clearer disease-mechanism-translational throughline than manuscripts first arrive with.

If that still sounds like the paper, an Experimental and Molecular Medicine submission readiness check is usually more valuable than cosmetic revision.

The impact factor does not tell you whether the translational bridge in your paper is convincing. EMM still expects the disease consequence to feel earned, not decorated. A mechanistic result plus a paragraph about therapeutic promise is often not enough.

That is where many submissions get misread by their own authors. The citation profile makes the journal look broadly permissive. In practice, the journal is selective about whether mechanism, disease meaning, and translational consequence form one coherent story.

That distinction becomes especially visible on papers built around one attractive dataset but an underdeveloped biomedical argument.